izpis_h1_title_alt

Advances in cholinesterase inhibitor research : an overview of preclinical studies of selected organoruthenium(II) complexes
ID Žužek, Monika C. (Avtor)

.pdfPDF - Predstavitvena datoteka, prenos (914,67 KB)
MD5: 1C6B4B8DBA20C8B74A8833FADD336B93
URLURL - Izvorni URL, za dostop obiščite https://www.mdpi.com/1422-0067/25/16/9049 Povezava se odpre v novem oknu

Izvleček
Cholinesterase (ChE) inhibitors are crucial therapeutic agents for the symptomatic treatment of certain chronic neurodegenerative diseases linked to functional disorders of the cholinergic system. Significant research efforts have been made to develop novel derivatives of classical ChE inhibitors and ChE inhibitors with novel scaffolds. Over the past decade, ruthenium complexes have emerged as promising novel therapeutic alternatives for the treatment of neurodegenerative diseases. Our research group has investigated a number of newly synthesized organoruthenium(II) complexes for their inhibitory activity against acetylcholinesterase (AChE) and butyrylcholinesterase (BChE). Three complexes (C1a, C1-C, and C1) inhibit ChE in a pharmacologically relevant range. C1a reversibly inhibits AChE and BChE without undesirable peripheral effects, making it a promising candidate for the treatment of Alzheimer’s disease. C1-Cl complex reversibly and competitively inhibits ChEs, particularly AChE. It inhibits nerve-evoked skeletal muscle twitch and tetanic contraction in a concentration-dependent manner with no effect on directly elicited twitch and tetanic contraction and is promising for further preclinical studies as a competitive neuromuscular blocking agent. C1 is a selective, competitive, and reversible inhibitor of BChE that inhibits horse serum BChE (hsBChE) without significant effect on the peripheral neuromuscular system and is a highly species-specific inhibitor of hsBChE that could serve as a species-specific drug target. This research contributes to the expanding knowledge of ChE inhibitors based on ruthenium complexes and highlights their potential as promising therapeutic candidates for chronic neurodegenerative diseases.

Jezik:Angleški jezik
Ključne besede:cholinesterases, enzyme inhibition, organoruthenium complex, neuromuscular junction, mouse, enzymes
Vrsta gradiva:Članek v reviji
Tipologija:1.02 - Pregledni znanstveni članek
Organizacija:VF - Veterinarska fakulteta
Status publikacije:Objavljeno
Različica publikacije:Objavljena publikacija
Leto izida:2024
Št. strani:14 str.
Številčenje:Vol. 25, iss. 16, art. 9049
PID:20.500.12556/RUL-160379 Povezava se odpre v novem oknu
UDK:616-092
ISSN pri članku:1422-0067
DOI:10.3390/ijms25169049 Povezava se odpre v novem oknu
COBISS.SI-ID:205157635 Povezava se odpre v novem oknu
Datum objave v RUL:27.08.2024
Število ogledov:108
Število prenosov:28
Metapodatki:XML RDF-CHPDL DC-XML DC-RDF
:
Kopiraj citat
Objavi na:Bookmark and Share

Gradivo je del revije

Naslov:International journal of molecular sciences
Skrajšan naslov:Int. j. mol. sci.
Založnik:MDPI
ISSN:1422-0067
COBISS.SI-ID:2779162 Povezava se odpre v novem oknu

Licence

Licenca:CC BY 4.0, Creative Commons Priznanje avtorstva 4.0 Mednarodna
Povezava:http://creativecommons.org/licenses/by/4.0/deed.sl
Opis:To je standardna licenca Creative Commons, ki daje uporabnikom največ možnosti za nadaljnjo uporabo dela, pri čemer morajo navesti avtorja.
Začetek licenciranja:27.08.2024

Projekti

Financer:ARIS - Javna agencija za znanstvenoraziskovalno in inovacijsko dejavnost Republike Slovenije
Številka projekta:P4-0053
Naslov:Endokrini, imunski in encimski odzivi pri zdravih in bolnih živalih

Podobna dela

Podobna dela v RUL:
Podobna dela v drugih slovenskih zbirkah:

Nazaj